SHALLCROSS STEVEN A (CEO and CFO) purchased 12.4% of their position (26K shares) of THERIVA BIOLOGICS, INC. on the open market
Open‑market purchase worth $16.5K — a moderate purchase. The strongest form of insider conviction signal.
P · 1 purchase
Filed: 6/7/2023ACC: 0001104659-23-068719
DirectorOfficer· CEO and CFO
Since Dec 2018
+26K
Net shares
Net buyer
$16.5K
Total acquired
1
Open market trades
1B · 0S
1
Total transactions
26K acquired
Non-Derivative Transactions1
Common Stock
Direct
Shares
+26K
Price / share
$0.63
Trade value
$16.45K
% of position
12.4%
6/6/2023
210K→236K
Total
Net shares
+26K
Net value
$16.45K
| Security | Date | Type | Shares | Price / Share | Trade Value | % of Position | Held Before | Held After |
|---|---|---|---|---|---|---|---|---|
| Common Stock Direct | 6/6/2023 | P · Purchase | +26K | $0.63 | $16.45K | 12.4% | 210K | 236K |
| Total | +26K | $16.45K | ||||||
Derivative Transactions0
No derivative transactions reported